Can Wegovy Affect Your Vision? The Evidence, the Risks, and What to Watch For

The misconception worth clearing up first: Wegovy does not simply 'cause eye problems'

If you've read that semaglutide causes blindness or irreversible eye damage, it's worth pausing there. That framing conflates two quite different things. One (diabetic retinopathy worsening) is a well-characterised phenomenon tied to fast glucose change, not the medicine itself. The other (a rare optic nerve condition called NAION) emerged from a 2024 study and has since prompted active research, but has not been confirmed as a direct causal link. Neither is a reason to avoid treatment if you're clinically suitable; both are reasons to go into treatment informed.

Our clinical team at nume reviews every patient's history before any prescription is written, and that assessment includes conditions or risk factors that touch on ocular health. A prescriber (not a form, not software) reads your answers. That matters here.

The broader question of how Wegovy can affect your eyes covers both pathways in more detail, including the anatomy. This page focuses on the vision question specifically and what the current evidence says.

Why blood-sugar control during Wegovy treatment can temporarily affect sight

This pathway is most relevant to people using Wegovy alongside a diagnosis of type 2 diabetes, or those who had poorly controlled blood sugar before starting. Semaglutide lowers blood glucose, often significantly and quickly. The lens and retinal vessels of the eye are sensitive to glucose concentration; when levels drop rapidly after years of being elevated, those tissues can react, sometimes causing transient blurring or, in rarer cases, a worsening of existing diabetic retinopathy.

This phenomenon was documented in the SUSTAIN-6 cardiovascular trial of semaglutide, which reported a higher rate of diabetic retinopathy complications in the treatment group compared with placebo. Importantly, the current consensus is that the mechanism is rapid glucose normalisation, not a toxic effect of the drug on the retina. The NHS notes this on its semaglutide medicines page.

If you have a history of diabetic eye disease, tell your prescriber before starting. Ophthalmology review and more gradual dose titration may be appropriate. Blurring that begins in the first weeks of treatment and settles is different from new, sudden vision loss, the former may be transient adjustment; the latter needs same-day assessment.

People asking specifically whether semaglutide can cause blurry vision often have this mechanism in mind.

NAION: the optic nerve finding that made headlines in 2024

In July 2024, a study published in JAMA Ophthalmology reported that people taking semaglutide for weight management had a higher observed rate of non-arteritic anterior ischaemic optic neuropathy (NAION) compared with those taking other weight-loss medicines. NAION is a sudden, usually painless loss of vision caused by reduced blood flow to the optic nerve. It is rare in the general population, estimates range from around two to ten cases per 100,000 people per year.

The study was observational, meaning it identified an association, not a proven cause. The authors noted that obesity itself is a risk factor for NAION, which complicates interpretation. The MHRA is monitoring this signal as part of ongoing post-marketing surveillance, and Wegovy carries a Black Triangle (▼) designation indicating additional monitoring is in place. You can review the current evidence landscape and report any suspected effects via the MHRA Yellow Card scheme.

Known risk factors for NAION include diabetes, high blood pressure, obstructive sleep apnoea, and a structurally small optic nerve disc, conditions that overlap considerably with the population using weight-loss medicines. If you have a history of NAION in one eye, discuss the risk carefully with a specialist before starting any GLP-1 treatment. If you experience sudden vision loss in one eye at any point during treatment, seek emergency care that day.

There is further detail on the research context in our page covering semaglutide and vision, and if you are also experiencing unexpected side effects such as persistent hiccups, our guide on hiccups and Wegovy explains what is known about that symptom too.

Practical steps: before you start, during treatment, and if something changes

Before starting, let your prescriber know if you have: existing diabetic retinopathy, a previous episode of NAION, high blood pressure, obstructive sleep apnoea, or any history of optic nerve problems. These are not automatic contraindications, but they inform the clinical picture. Our clinical team takes a thorough medical history for exactly this reason.

During treatment, attend any planned eye appointments as usual and mention that you are taking semaglutide. If you notice gradual, mild blurring in the first few weeks of a new dose, note it and raise it at your next prescriber check-in, it may be transient. Patients who want a closer look at how treatment can affect sight over time may find our dedicated page on Wegovy and vision changes a useful reference alongside their prescriber conversations. The symptom profile that demands same-day medical attention is different: sudden loss of vision, a missing patch in your visual field, or vision that worsens over hours in one eye. Call 111 or attend A&E; do not email your clinic.

Wegovy also carries other side effects unrelated to vision. For a broader picture of what to expect, our Wegovy overview covers the full licensed profile, and our FAQs address many of the practical questions patients raise after starting.

If you have questions about how these considerations apply to your own health history, a free consultation with a GPhC-registered prescriber at nume is the right next step. They can review your circumstances and, if Wegovy is clinically appropriate, guide you on what to watch for. Start your free consultation to speak with someone today.